Kayla joined Pivotal bioVenture Partners in 2024. Previously, she was an investment banking analyst at Evercore, focusing on life sciences and biotechnology. At Evercore, she assisted in advising on over $1.7 billion worth of transactions across M&A and capital raising. Kayla earned a BS in finance from New York University. She wrote her honors thesis on the relationship between drug pipeline composition and company valuation.
